Literature DB >> 8262620

Effect of treatment on titer, function, and antigen recognition of serum antibodies to Actinobacillus actinomycetemcomitans in patients with rapidly progressive periodontitis.

K Sjöström1, J Ou, C Whitney, B Johnson, R Darveau, D Engel, R C Page.   

Abstract

Although periodontal treatment by scaling and root planing (SCRP) is known to induce bacteremia, the effect of this procedure on the host immune response is not known. We have determined pre- and post-SCRP immunoglobulin G antibody titers to antigens of Actinobacillus actinomycetemcomitans in the sera of 22 patients with rapidly progressive periodontitis. We also assessed the ability of these sera to enhance phagocytosis and killing of A. actinomycetemcomitans by human polymorphonuclear leukocytes by using a polymorphonuclear leukocyte chemiluminescence (CL) assay. Specific anti-A. actinomycetemcomitans antibody titers were significantly increased at 6 and 12 months after beginning treatment, and CL values were significantly increased at 12 months, whereas mean interproximal pocket depths were significantly decreased at 12 months after beginning treatment. When patients were classified as either seropositive (twice the median titer of control subjects; n = 10) or seronegative (n = 12), both median titers and CL values were significantly increased for the seronegative group at 6 and 12 months after treatment. In the seropositive group, only the median titer was significantly increased at 12 months. Western blot (immunoblot) patterns for six seronegative and six seropositive patients differed remarkably at the baseline. Before treatment, all of the seropositive patients recognized high-molecular-mass lipopolysaccharide (LPS) and a large number of protein components. Patterns were virtually unaffected by therapy. Before treatment, only one of the seronegative patients recognized the LPS smear and none reacted strongly with protein components. Following treatment, slight LPS staining was observed for five of six seronegative patients and detection of protein bands was enhanced in all cases. We conclude that treatment by SCRP induces a humoral immune response, especially in seronegative patients, and that response may play a role in the observed beneficial effects of periodontal treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8262620      PMCID: PMC186079          DOI: 10.1128/iai.62.1.145-151.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Humoral immune responses to Porphyromonas gingivalis before and following therapy in rapidly progressive periodontitis patients.

Authors:  H A Chen; B D Johnson; T J Sims; R P Darveau; B J Moncla; C W Whitney; D Engel; R C Page
Journal:  J Periodontol       Date:  1991-12       Impact factor: 6.993

2.  Opsonic IgG antibody against Actinobacillus actinomycetemcomitans in localized juvenile periodontitis.

Authors:  P J Baker; M E Wilson
Journal:  Oral Microbiol Immunol       Date:  1989-06

3.  Relationship of serum antibody to attachment level patterns in young adults with juvenile periodontitis or generalized severe periodontitis.

Authors:  J C Gunsolley; J A Burmeister; J G Tew; A M Best; R R Ranney
Journal:  J Periodontol       Date:  1987-05       Impact factor: 6.993

4.  Actinobacillus actinomycetemcomitans and Bacteroides intermedius in human periodontitis: age relationship and mutual association.

Authors:  J Slots; D Feik; T E Rams
Journal:  J Clin Periodontol       Date:  1990-10       Impact factor: 8.728

5.  The immunodominant outer membrane antigen of Actinobacillus actinomycetemcomitans is located in the serotype-specific high-molecular-mass carbohydrate moiety of lipopolysaccharide.

Authors:  R C Page; T J Sims; L D Engel; B J Moncla; B Bainbridge; J Stray; R P Darveau
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

6.  Evidence that the serotype b antigenic determinant of Actinobacillus actinomycetemcomitans Y4 resides in the polysaccharide moiety of lipopolysaccharide.

Authors:  M E Wilson; R E Schifferle
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

7.  Antigens of Actinobacillus actinomycetemcomitans recognized by patients with juvenile periodontitis and periodontally normal subjects.

Authors:  T J Sims; B J Moncla; R P Darveau; R C Page
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

8.  Immunodominant antigen of Actinobacillus actinomycetemcomitans Y4 in high-responder patients.

Authors:  J V Califano; H A Schenkein; J G Tew
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

9.  Serum immunoglobulin G antibody to Porphyromonas gingivalis in rapidly progressive periodontitis: titer, avidity, and subclass distribution.

Authors:  C Whitney; J Ant; B Moncla; B Johnson; R C Page; D Engel
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

10.  Multicenter evaluation of tetracycline fiber therapy: II. Clinical response.

Authors:  J M Goodson; M A Cugini; R L Kent; G C Armitage; C M Cobb; D Fine; M E Fritz; E Green; M J Imoberdorf; W J Killoy
Journal:  J Periodontal Res       Date:  1991-07       Impact factor: 4.419

View more
  6 in total

1.  The effect of apically repositioned flap surgery on clinical parameters and the composition of the subgingival microbiota: 12-month data.

Authors:  Rustin M Levy; William V Giannobile; Magda Feres; Anne D Haffajee; Claire Smith; Sigmund S Socransky
Journal:  Int J Periodontics Restorative Dent       Date:  2002-06       Impact factor: 1.840

2.  Initial serum antibody titer to Porphyromonas gingivalis influences development of antibody avidity and success of therapy for chronic periodontitis.

Authors:  J Mooney; E Adonogianaki; M P Riggio; K Takahashi; A Haerian; D F Kinane
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

3.  Multifactorial assessment of predictors for prevention of periodontal disease progression.

Authors:  Benjamin Ehmke; Thomas Beikler; Imme Haubitz; Helge Karch; Thomas Frank Flemmig
Journal:  Clin Oral Investig       Date:  2003-08-26       Impact factor: 3.573

4.  Immunization against Porphyromonas gingivalis inhibits progression of experimental periodontitis in nonhuman primates.

Authors:  G R Persson; D Engel; C Whitney; R Darveau; A Weinberg; M Brunsvold; R C Page
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

5.  The Subgingival Plaque Microbiome, Systemic Antibodies Against Bacteria and Citrullinated Proteins Following Periodontal Therapy.

Authors:  Emily Davison; William Johnston; Krystyna Piela; Bob T Rosier; Michael Paterson; Alex Mira; Shauna Culshaw
Journal:  Pathogens       Date:  2021-02-10

6.  Rheumatoid Arthritis-Associated Autoimmunity Due to Aggregatibacter actinomycetemcomitans and Its Resolution With Antibiotic Therapy.

Authors:  Amarshi Mukherjee; Vanessa Jantsch; Rida Khan; Wolfgang Hartung; René Fischer; Jonathan Jantsch; Boris Ehrenstein; Maximilian F Konig; Felipe Andrade
Journal:  Front Immunol       Date:  2018-10-16       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.